Specifically, we performed an exploratory analysis of SPARC expression in patients with available tumor specimens that were enrolled on a randomized phase II study examining patient outcomes from treatment with one of two neo/adjuvant chemotherapy regimens for soft tissue sarcoma, doxorubicin and ifosfamide (AI) and gemcitabine and docetaxel (GT). Here, SPARC is linked to soft tissue sarcoma.